$SMMT · Summit Therapeutics Inc.
Summit Therapeutics entered into a securities purchase agreement with AstraZeneca Holdings B.V. for the sale of ~108,955 shares of newly designated Class A Convertible Preferred Stock at $18,356.14 per share, yielding $2.0 billion in gross proceeds. Each preferred share converts into 1,000 common shares, implying a common stock price of $18.36 — a 10% premium to the prior week's five-day VWAP. Concurrently, the companies announced a clinical trial collaboration combining ivonescimab with AstraZeneca's sonesitatug vedotin in GI cancers, plus a non-binding MOU to expand combinations across Astra
- AstraZeneca will purchase ~108,955 preferred shares convertible at 1:1,000 into common stock for $2.0 billion in gross proceeds.
- The purchase price equates to $18.36 per common share, a 10% premium over the prior week's five-day VWAP.
- Summit and AstraZeneca entered a clinical collaboration to evaluate ivonescimab combined with sonesitatug vedotin in GI cancers.
- A non-binding MOU covers additional trials combining ivonescimab with AstraZeneca's broader ADC portfolio.
- Summit's ivonescimab PDUFA date with the FDA for EGFR-mutated NSCLC is November 14, 2026.
Extended-hours trading shows SMMT at $18.21, up 17.61% from the $15.48 regular close, reflecting strong investor enthusiasm for the AstraZeneca validation and premium pricing. The $2B investment on a $12.35B market cap represents a significant strategic endorsement.
AstraZeneca's $2B equity investment at a premium validates ivonescimab's bispecific platform and signals pharma conviction ahead of the November 2026 PDUFA decision.
This deal mirrors the pharma trend of large-cap players taking strategic equity stakes in biotechs with late-stage bispecific assets. AstraZeneca's ADC portfolio plus ivonescimab's PD-1/VEGF bispecific mechanism targets the same combination paradigm driving deals like Merck-Daiichi and Pfizer-Seagen
The MOU for the broader ADC combination collaboration is non-binding with no assurance of completion. Closing of the $2B private placement is subject to customary conditions, and dilution from conversion of preferred shares could pressure the stock. Registration rights require filing within 60 days,
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.